Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy

Not Recruiting

Trial ID: NCT04417088


The purpose of this study is to evaluate the safety and feasibility of the Exablate Model 4000 Type 2 system when used as a tool to open the blood-brain-barrier (BBB) in subjects with recurrent glioblastoma (rGBM) undergoing carboplatin monotherapy.

Official Title

Assessment of Safety and Feasibility of Exablate Type 2 for Blood-Brain Barrier Disruption (BBBD) With Microbubble Resonators for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin Monotherapy

Stanford Investigator(s)

Seema Nagpal, MD
Seema Nagpal, MD

Clinical Professor, Neurology & Neurological Sciences Clinical Professor (By courtesy), Neurosurgery

Gordon Li, MD
Gordon Li, MD

Professor of Neurosurgery and, by courtesy, of Neurology and of Otolaryngology - Head & Neck Surgery (OHNS)


Inclusion Criteria:

   - Must be between 18-80 years old

   - Histologically confirmed glioblastoma

   - Planned for Carboplatin monotherapy

   - Be willing and able to provided written informed consent/asent

   - Tumor progression after first line chemo radiation

   - Recovered to grade 0 or 1 or pre-treatment baseline from clinically significant toxic
   effects of prior therapy

   - Women of childbearing potential is confirmed not pregnant. Male and Female subjects
   utilize highly effective contraception

   - Able to communicate verbally

Exclusion Criteria:

   - Acute intracranial hemorrhage

   - Ferrous metallic implanted objects in the skull or brain

   - Prior toxicity with carboplatin chemotherapy

   - Women who are pregnant or breastfeeding

   - Cerebellar spinal cord or brain stem tumor

   - Known active Hepatitis B or Hepatitis C or HIV

   - Significant depression not adequately controlled

   - Has previously received anti-VEGF or anti-VEGF agents like Avastin

   - Cardiac disease or unstable hemodynamics

   - Severe hypertension

   - History of a bleeding disorder, coagulopathy or with a history of spontaneous tumor

   - Active drug or alcohol use disorder

   - Known sensitivity to gadolinium-based contrast agents

   - Known sensitivity or contraindications to ultrasound contrast agent or perflutren

   - Unable to undergo MRI or contraindications to MRI such as non-MRI compatible implanted

   - Difficulty lying supine and still or severe claustrophobia which cannot be managed
   with medication

   - Severely impaired renal function

   - Right to left or bi-directional cardiac shunt

   - Cranial or systemic infection requiring antibiotics

   - Known additional malignancy that is progression or require active treatment


drug: Carboplatin

device: Exablate BBBD

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Hari Priya Yerraballa, MBBS

New Trial Alerts

Receive email alerts when trials open to patients.